Vesalius Therapeutics
Vesalius Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019 by Flagship Pioneering. The company is dedicated to improving the treatment of common diseases that significantly impact human health. Vesalius utilizes its innovative platform, Continuum Discovery™, which combines artificial intelligence and machine learning with human phenotypic data and genetics. This approach helps identify new drug targets and develop effective therapies for conditions such as heart failure, high blood pressure, type II diabetes, Alzheimer’s disease, NASH, and obesity. The platform also supports efficient clinical trials, enhancing the likelihood of successful outcomes. The company has formed a strategic partnership with GlaxoSmithKline to explore novel treatments for Parkinson’s disease, showcasing its commitment to collaborative innovation. Vesalius Therapeutics has received substantial funding to advance its research and development efforts.
Work at Vesalius Therapeutics in HR or recruiting? Claim this page
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Mar 2022 | Venture | $75M | 1 |
H-1B sponsorship
The department split adds up all the years listed above. FY2025 alone: 1 filings.
Peer reviews
Worked with someone at Vesalius Therapeutics?
Anonymous peer reviews on OffTheRecord
Hiring now
Similar companies
Vesalius Therapeutics FAQ
How many employees does Vesalius Therapeutics have?
Vesalius Therapeutics has about 34 employees (as of Nov 2026).
Does Vesalius Therapeutics sponsor H1B visas?
Yes. Vesalius Therapeutics filed 1 H1B (LCA) application in FY2025, according to the latest U.S. Department of Labor disclosures. It was for a Operations role.
How much funding has Vesalius Therapeutics raised?
Vesalius Therapeutics has raised $75M in total funding.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.